SNDX Share Price Performance
US$12.57
-7.09 (-36.06%)
61.5% undervalued intrinsic discount
US$32.67
Fair Value
Price US$12.57
AnalystConsensusTarget US$32.67
Fair ValueUS$32.67
Share PriceUS$12.57
61.5% undervalued intrinsic discount
SNDX Community Narratives
AN
Fair Value US$32.67 68.2% undervalued intrinsic discount
FDA Approvals Will Expand AML And cGVHD Treatment Options
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
SNDX Community Fair Values
- US$32.67FV68.2% undervalued intrinsic discount117.82%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative3users have followed this narrative13 days ago author updated this narrative
Recent SNDX News & Updates
No updates
Syndax Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.85
- Gross Margin
- -456.60%
- Net Profit Margin
- -757.52%
- Debt/Equity Ratio
- 159.9%
Syndax Pharmaceuticals, Inc. Competitors
About SNDX
- Founded
- 2005
- Employees
- 270
- CEO
- WebsiteView website
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading